Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:IMVT NASDAQ:KRYS NASDAQ:OCGN NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.59-4.8%$1.44$0.87▼$6.78$166.99M0.74827,427 shs299,435 shsIMVTImmunovant$17.91-2.0%$15.78$12.72▼$34.47$3.13B0.631.22 million shs1.03 million shsKRYSKrystal Biotech$147.49-1.8%$136.27$122.80▼$219.34$4.34B0.67287,068 shs303,976 shsOCGNOcugen$1.02+2.0%$0.96$0.52▼$1.77$292.03M4.184.55 million shs3.09 million shsRGNXREGENXBIO$8.16-6.1%$8.96$5.04▼$15.36$435.89M1.06926,270 shs742,903 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+7.05%-2.91%+9.87%+81.50%-71.36%IMVTImmunovant+2.64%+4.46%+19.40%+20.66%-39.03%KRYSKrystal Biotech+0.05%+0.27%+15.48%-10.93%-27.57%OCGNOcugen-3.85%-13.04%-8.26%+47.19%-45.36%RGNXREGENXBIO+2.24%-4.08%+0.35%+46.30%-34.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.8882 of 5 stars3.12.00.04.52.72.50.0IMVTImmunovant1.3768 of 5 stars3.40.00.00.02.21.70.0KRYSKrystal Biotech4.5474 of 5 stars3.51.00.04.72.23.31.9OCGNOcugen1.2823 of 5 stars3.51.00.00.02.10.00.0RGNXREGENXBIO4.041 of 5 stars3.41.00.04.61.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00151.57% UpsideIMVTImmunovant 2.82Moderate Buy$36.30102.68% UpsideKRYSKrystal Biotech 3.00Buy$213.7544.93% UpsideOCGNOcugen 3.00Buy$6.00488.24% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63287.56% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, RGNX, KRYS, IMVT, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.007/9/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.006/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/9/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.58N/AN/A$1.29 per share1.23IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AKRYSKrystal Biotech$290.52M14.67$4.55 per share32.38$32.90 per share4.48OCGNOcugen$4.05M73.55N/AN/A$0.10 per share10.20RGNXREGENXBIO$83.33M4.91N/AN/A$5.24 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.260.00N/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)IMVTImmunovant-$413.84M-$2.740.00N/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1633.4414.63N/A37.17%14.64%13.28%8/4/2025 (Estimated)OCGNOcugen-$54.05M-$0.190.00N/AN/A-1,271.12%-223.00%-92.20%8/1/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.110.00N/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)Latest ALEC, RGNX, KRYS, IMVT, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025RGNXREGENXBIO-$1.13N/AN/AN/AN/AN/A8/6/2025Q2 2025ALECAlector-$0.45N/AN/AN/A$2.76 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A8/1/2025Q2 2025OCGNOcugen-$0.06N/AN/AN/A$0.35 millionN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34IMVTImmunovantN/A11.1611.16KRYSKrystal BiotechN/A9.659.27OCGNOcugen1.742.602.60RGNXREGENXBION/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%IMVTImmunovant47.08%KRYSKrystal Biotech86.29%OCGNOcugen10.27%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%IMVTImmunovant1.80%KRYSKrystal Biotech13.70%OCGNOcugen4.42%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableIMVTImmunovant120171.07 million167.99 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableOCGNOcugen80292.03 million279.12 millionOptionableRGNXREGENXBIO37050.16 million43.75 millionOptionableALEC, RGNX, KRYS, IMVT, and OCGN HeadlinesRecent News About These CompaniesREGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the companyJuly 18 at 11:43 AM | finance.yahoo.comREGENXBIO Announces Publication of Preclinical Results Demonstrating ...July 11, 2025 | morningstar.comMREGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular DystrophyJuly 10, 2025 | prnewswire.comRGNX | REGENXBIO Inc. Annual Income Statement - MarketWatchJuly 6, 2025 | marketwatch.comJanney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)July 4, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 30, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Regenxbio Through 8 AnalystsJune 9, 2025 | benzinga.comRegenxbio's RGX-121 Could Become The New Standard Of Care In Hunter SyndromeJune 6, 2025 | seekingalpha.comOtsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne updateJune 6, 2025 | biopharmadive.comBRegeNXBio shares fall, despite positive new data on RGX-202June 6, 2025 | thepharmaletter.comTRegenxbio’s Duchenne gene therapy data positive as shares falterJune 5, 2025 | bioworld.comBRegenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene TherapyJune 5, 2025 | biospace.comBREGENXBIO updates Phase 1/2 data for Duchenne candidateJune 5, 2025 | msn.comEarly Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, LongerJune 5, 2025 | benzinga.comREGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202June 5, 2025 | prnewswire.comREGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202June 2, 2025 | prnewswire.comRegenxbio at RBC Conference: Strategic Moves and Clinical ProgressMay 22, 2025 | investing.comREGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 20, 2025 | finanznachrichten.deREGENXBIO announces royalty monetization agreement for up to $250MMay 20, 2025 | msn.comREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 19, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in StockMay 15, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, RGNX, KRYS, IMVT, and OCGN Company DescriptionsAlector NASDAQ:ALEC$1.59 -0.08 (-4.79%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.31%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Immunovant NASDAQ:IMVT$17.91 -0.37 (-2.02%) Closing price 04:00 PM EasternExtended Trading$18.03 +0.12 (+0.67%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Krystal Biotech NASDAQ:KRYS$147.49 -2.66 (-1.77%) Closing price 04:00 PM EasternExtended Trading$147.40 -0.09 (-0.06%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Ocugen NASDAQ:OCGN$1.02 +0.02 (+2.00%) Closing price 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.49%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.REGENXBIO NASDAQ:RGNX$8.16 -0.53 (-6.10%) Closing price 04:00 PM EasternExtended Trading$8.28 +0.12 (+1.48%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.